Get the Stockscreener App
10.09
3.70%
0.36
Design Therapeutics Inc stock is traded at $10.09, with a volume of 166.38K.
It is up +3.70% in the last 24 hours and down -17.46% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
See More
Previous Close:
$9.73
Open:
$9.81
24h Volume:
166.38K
Relative Volume:
0.29
Market Cap:
$631.45M
Revenue:
Net Income/Loss:
$-69.71M
P/E Ratio:
-8.4541
EPS:
-1.1935
Net Cash Flow:
$-54.12M
1W Performance:
-12.18%
1M Performance:
-17.46%
6M Performance:
-20.86%
1Y Performance:
+50.37%
1-Day Range:
$9.805
$10.09
1-Week Range:
$9.475
$11.92
52-Week Range:
$5.28
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
10.09 | 631.45M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-26 | Initiated | Wells Fargo | Overweight |
| May-12-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-16-26 | Initiated | Jefferies | Buy |
| Jan-07-26 | Initiated | Oppenheimer | Outperform |
| Dec-03-25 | Initiated | Craig Hallum | Buy |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-20-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027 - Seeking Alpha
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance UK
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target - marketscreener.com
tm2619715-5_s1none30.1514628s - SEC.gov
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Australia
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Singapore
Solid Biosciences (Nasdaq:SLDB)Stock Analysis - Simply Wall Street
Seres Therapeutics (Nasdaq:MCRB)Stock Analysis - Simply Wall Street
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to S&P Biotechnology Select Industry Index - marketscreener.com
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com Australia
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com South Africa
Design Therapeutics at Cantor conference: biomarker push takes center stage - Investing.com
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com Canada
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com India
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com UK
DSGN: DT-216 achieved robust biomarker and clinical gains in FA, with pivotal data expected in Q1 2027 - TradingView
A biotech company's conference chat will be webcast live Sept. 9. - Stock Titan
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Risk Parity Rebalance - vinanet.vn
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Corrective Wave - careplusvn.com
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Wide Range Bar - dars.gov.et
Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - sahmcapital.com
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch - Yahoo Finance
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch - AOL.com
Design Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
DSGN Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesFiscal Year Earnings - vinanet.vn
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.06% Stock GainMid-Term Outlook - Vinanet
Design Therapeutics Stock Price Forecast. Should You Buy DSGN? - StockInvest.us
Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares - Stock Titan
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake - Stock Titan
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co. - MarketBeat
Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - finance.yahoo.com
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplinePreliminary Results - vinanet.vn
Renaissance Technologies LLC Buys 121,100 Shares of Design Therapeutics, Inc. $DSGN - MarketBeat
Design Therapeutics (DSGN) Rises 1.47% as Gene Therapy Plays Draw AttentionRectangle Pattern - dars.gov.et
Design Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Design Therapeutics Q2 Net Loss Narrows - Moomoo
Design Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Design Therapeutics posts Q2 loss, updates clinical trials - Investing.com
Design Therapeutics Q2 Net Loss Narrows - marketscreener.com
Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - marketbeat.com
Design Therapeutics Q2 net loss narrower than expected - TradingView
Design Therapeutics reports $20.2M Q2 net loss, $207.4M cash as RESTORE-FA advances - TradingView
Design Therapeutics, Inc. 2Q 2026: Net loss $(20,165)K, EPS $(0.32) — 10-Q Summary - TradingView
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial - Moomoo
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Design Therapeutics Inc Stock (DSGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Logos Global Master Fund LP | Director |
Nov 14 '25 |
Proposed Sale |
7.06 |
620,000 |
4,377,200 |
0 |
| Logos Global Master Fund LP | Director |
Nov 07 '25 |
Proposed Sale |
6.87 |
415,000 |
2,851,050 |
0 |
12.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):